{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:56:50Z","timestamp":1793858210186,"version":"4.6.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmoop.2026.108338","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:12:20Z","timestamp":1787141540000},"page":"108338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7521-1596","authenticated-orcid":false,"given":"T.","family":"Masuishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7579-1175","authenticated-orcid":false,"given":"J.H.","family":"Strickler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kuboki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6554-5488","authenticated-orcid":false,"given":"M.","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Galot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.J.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4653-6324","authenticated-orcid":false,"given":"E.","family":"\u00c9lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2681-2846","authenticated-orcid":false,"given":"S.","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Nolte-Hippenmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Nduka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0929-0783","authenticated-orcid":false,"given":"N.","family":"Strydom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2026.108338_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","article-title":"Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial","volume":"23","author":"Fakih","year":"2022","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2026.108338_bib2","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.esmoop.2026.108338_bib3","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1200\/JCO-24-02026","article-title":"Overall survival analysis of the phase III CodeBreaK 300 study of sotorasib plus panitumumab versus investigator\u2019s choice in chemorefractory KRAS G12C colorectal cancer","volume":"43","author":"Pietrantonio","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108338_bib5","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108338_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110993","article-title":"KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy","volume":"39","author":"Ryan","year":"2022","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108338_bib7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41591-023-02717-6","article-title":"Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial","volume":"30","author":"Kuboki","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108338_bib8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2026.108338_bib9","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1158\/1538-7445.AM2023-2308","article-title":"Abstract 2308: Biomarkers of acquired resistance to sotorasib (soto) plus panitumumab (pani) in chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC)","volume":"83","author":"Hong","year":"2023","journal-title":"Cancer Res"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.108338_bib10","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1200\/JCO.2025.43.16_suppl.3540","article-title":"Biomarkers of emergent resistance to sotorasib plus panitumumab in KRAS G12C-mutated metastatic colorectal cancer (mCRC) from the randomized, phase 3 CodeBreaK 300 study","volume":"43","author":"Salvatore","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108338_bib11","first-page":"994","article-title":"Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts","volume":"8","author":"Prewett","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108338_bib12","doi-asserted-by":"crossref","first-page":"958","DOI":"10.2174\/138161213804547204","article-title":"Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models","volume":"19","author":"Petitprez","year":"2013","journal-title":"Curr Pharm Des"},{"issue":"31","key":"10.1016\/j.esmoop.2026.108338_bib13","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"Peeters","year":"2010","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.esmoop.2026.108338_bib14","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108338_bib15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108338_bib16","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","article-title":"Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study","volume":"22","author":"Bokemeyer","year":"2011","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2026.108338_bib17","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108338_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cct.2017.04.006","article-title":"A Bayesian interval dose-finding design addressing Ockham\u2019s razor: mTPI-2","volume":"58","author":"Guo","year":"2017","journal-title":"Contemp Clin Trials"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108338_bib20","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.3390\/ijms26062522","article-title":"What is next for refractory colorectal cancer CRC? Looking beyond SUNLIGHT, FRESCO2, RECURSE and CORRECT","volume":"26","author":"Cherri","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108338_bib21","article-title":"Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and\/or metastatic colorectal cancer","volume":"2","author":"Wulaningsih","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"10395","key":"10.1016\/j.esmoop.2026.108338_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"issue":"9863","key":"10.1016\/j.esmoop.2026.108338_bib23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.esmoop.2026.108338_bib24","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.esmoop.2026.108338_bib25","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108338_bib26","doi-asserted-by":"crossref","first-page":"e981","DOI":"10.1093\/oncolo\/oyad138","article-title":"Prevalence of KRAS G12C mutation and co-mutations and associated clinical outcomes in patients with colorectal cancer: a systematic literature review","volume":"28","author":"Strickler","year":"2023","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108338_bib27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/oncolo\/oyac077","article-title":"Real-world study of characteristics and treatment outcomes among patients with KRAS p.G12C-mutated or other KRAS mutated metastatic colorectal cancer","volume":"27","author":"Fakih","year":"2022","journal-title":"Oncologist"},{"issue":"17","key":"10.1016\/j.esmoop.2026.108338_bib28","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108338_bib29","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.22.01423","article-title":"Resistance mechanisms to anti-epidermal growth factor receptor therapy in RAS\/RAF wild-type colorectal cancer vary by regimen and line of therapy","volume":"41","author":"Parseghian","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108338_bib30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41591-023-02696-8","article-title":"Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial","volume":"30","author":"Desai","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2026.108338_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1380584","article-title":"KRAS G12C inhibitor combination therapies: current evidence and challenge","volume":"14","author":"Miyashita","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108338_bib32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.esmoop.2026.108338_bib33","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108338_bib34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/cpdd.35","article-title":"Pharmacokinetics of irinotecan with and without panitumumab coadministration in patients with metastatic colorectal cancer","volume":"2","author":"Yang","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2026.108338_bib35","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.3747\/co.v17is1.615","article-title":"Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer","volume":"17","author":"Fakih","year":"2010","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108338_bib36","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2217\/fon.14.251","article-title":"Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP","volume":"11","author":"Kobayashi","year":"2015","journal-title":"Future Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108338_bib37","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108338_bib38","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","article-title":"Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study)","volume":"11","author":"Muro","year":"2010","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2026.108338_bib39","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1158\/1078-0432.CCR-15-0526","article-title":"Analysis of KRAS\/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer","volume":"21","author":"Peeters","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.108338_bib40","article-title":"A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C-mutated metastatic colorectal cancer (CodeBreaK 301)","volume":"43","author":"Kim","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:39:54Z","timestamp":1792769994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926022805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2059702926022805"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108338","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108338"}}